• Citer

Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.

par Biganzoli, Laura ;Cufer, T;Bruning, Peter;Coleman, R;Duchateau, L;Calvert, A H;Gamucci, T;Twelves, C.;Fargeot, Pierre;Epelbaum, R;Lohrisch, C;Piccart-Gebhart, Martine
Référence Journal of clinical oncology, 20, 14, page (3114-3121)
Publication Publié, 2002-07

Article révisé par les pairs

• Détails
• Contenu

Titre:	Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Auteur:	Biganzoli, Laura; Cufer, T; Bruning, Peter; Coleman, R; Duchateau, L; Calvert, A H; Gamucci, T; Twelves, C.; Fargeot, Pierre; Epelbaum, R; Lohrisch, C; Piccart-Gebhart, Martine
Informations sur la publication:	Journal of clinical oncology, 20, 14, page (3114-3121)
Statut de publication:	Publié, 2002-07
Sujet CREF:	Sciences bio-médicales et agricoles
MeSH keywords:	Adult
	Aged
	Antineoplastic Combined Chemotherapy Protocols -- adverse effects
	Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
	Breast Neoplasms -- drug therapy
	Breast Neoplasms -- pathology
	Cyclophosphamide -- administration & dosage
	Disease Progression
	Disease-Free Survival
	Doxorubicin -- administration & dosage
	Drug Administration Schedule
	Europe
	Female
	Humans
	Middle Aged
	Paclitaxel -- administration & dosage
	Survival Analysis
	Treatment Outcome
Note générale:	Clinical Trial
	Clinical Trial, Phase III
	Journal Article
	Multicenter Study
	Randomized Controlled Trial
	Research Support, Non-U.S. Gov't
Langue:	Anglais
Identificateurs:	urn:issn:0732-183X
	info:pmid/12118025